Table 3.
Comparison of Baseline Characteristics According to Objective Response
| Characteristic | Objective response (n=30) | No objective response (n=81) | p-value |
|---|---|---|---|
| Age, yr | 63.2 (52.3–70.2) | 60.0 (51.5–68.4) | 0.496 |
| Male sex | 23 (76.7) | 64 (79.0) | 0.994 |
| Etiology | 0.302 | ||
| Non-viral | 4 (13.3) | 20 (24.7) | |
| Viral | 26 (86.7) | 61 (75.3) | |
| ALBI grade | 0.195 | ||
| 1 | 20 (66.7) | 41 (50.6) | |
| 2 | 10 (33.3) | 40 (49.4) | |
| AFP, ng/mL | 8.6 (3.4–196.0) | 102.0 (8.8–7,457) | 0.010 |
| PIVKA-II, mAU/mL | 603.0 (57.0–2,348) | 500.0 (59.5–5,062) | 0.965 |
| CRP, mg/dL | 0.4 (0.1–1.7) | 0.7 (0.2–2.8) | 0.532 |
| NLR | 0.704 | ||
| ≤4.0 | 22 (73.3) | 64 (79.0) | |
| >4.0 | 8 (26.7) | 17 (21.0) | |
| CTP class | 0.958 | ||
| A | 27 (90.0) | 75 (92.6) | |
| B | 3 (10.0) | 6 (7.4) | |
| CRAFITY score* | 0.280 | ||
| 0 | 9 (42.9) | 14 (25.9) | |
| 1 | 10 (47.6) | 29 (53.7) | |
| 2 | 2 (9.5) | 11 (20.4) | |
| BCLC | 1.000 | ||
| B | 5 (16.7) | 15 (18.5) | |
| C | 25 (83.3) | 66 (81.5) | |
| Macrovascular invasion | 11 (36.7) | 31 (38.3) | 1.000 |
| High-risk features | 9 (30.0) | 28 (34.6) | 0.821 |
| Prior local treatment | 20 (66.7) | 47 (58.0) | 0.543 |
| Combined RT | 12 (40.0) | 12 (14.8) | 0.009 |
| Lung metastasis | 3 (10.0) | 26 (32.1) | 0.035 |
| LN metastasis | 11 (36.7) | 19 (23.5) | 0.250 |
| Bone metastasis | 7 (23.3) | 12 (14.8) | 0.439 |
| Peritoneal seeding | 7 (23.3) | 2 (2.5) | 0.001 |
Data are presented as median (interquartile range) or number (%).
ALBI, albumin-bilirubin; AFP, a-fetoprotein; PIVKA, protein induced by vitamin K absence or antagonist; CRP, C-reactive protein; NLR, neutrophil-to-lymphocyte ratio; CTP, Child-Turcotte-Pugh; CRAFITY, C-reactive protein and α-fetoprotein in immunotherapy; BCLC, Barcelona Liver Cancer; RT, radiotherapy; LN, lymph node.
*Missing information on CRAFITY score for 36 patients.